60 Degrees Pharmaceuticals (SCTP) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
2 Jul, 2026Executive summary
The annual meeting will be held virtually on August 5, 2026, with voting available by phone or mail for shareholders of record as of July 2, 2026.
Key proposals include director elections, amendments to the equity incentive plan, a reverse stock split, auditor ratification, a management success fee, and potential adjournment to solicit more proxies.
The Board recommends voting in favor of all proposals, emphasizing alignment with shareholder interests and corporate governance best practices.
Voting matters and shareholder proposals
Shareholders will vote on electing five directors, increasing authorized shares under the 2022 Equity Incentive Plan by 800,000, approving a reverse stock split (1:5 to 1:10), ratifying RBSM LLP as auditor, approving a management success fee for qualifying transactions, and adjourning the meeting if needed.
The Board recommends a vote “FOR” all proposals and notes that no other business is expected at the meeting.
Shareholder proposals for the 2027 meeting must be submitted between 90 and 120 days before the anniversary of the 2026 meeting.
Board of directors and corporate governance
The Board consists of five directors, three of whom are independent under Nasdaq rules.
Board committees include Audit, Compensation, and Nominating and Corporate Governance, each with defined charters and responsibilities.
The Board met six times in 2025, with high attendance and regular executive sessions for non-management and independent directors.
The Nominating and Corporate Governance Committee considers diversity and experience in director nominations.
Latest events from 60 Degrees Pharmaceuticals
- Three evidence streams target a potential 2027 babesiosis sNDA, pending hospital unblinding.SCTP
Investor presentation - January 2027 hospital-trial results will determine the babesiosis regulatory path.SCTP
Investor update - Hospital study results are expected in January 2027; FDA discussions are planned.SCTP
Study update - Label expansion for ARAKODA into babesiosis advances, with pivotal milestones expected by 2028.SCTP
H.C. Wainwright 28th Annual Global Investment Conference - Registering 1.77M shares for resale, with focus on infectious disease therapies and Arakoda expansion.SCTP
Registration filing - Revenue more than doubled, but losses widened and cash runway remains a major concern.SCTP
Q2 2026 - ARAKODA drives growth in malaria and babesiosis markets, with profitability targeted by 2028.SCTP
Investor presentation - Shareholders will vote on director elections, equity plan expansion, a reverse split, and key governance items.SCTP
Proxy filing - Label expansion and clinical trials could triple platform value by 2028.SCTP
H.C. Wainwright 27th Annual Global Investment Conference